Format

Send to

Choose Destination
Clin Proteomics. 2018 Sep 19;15:30. doi: 10.1186/s12014-018-9206-0. eCollection 2018.

Proteomic analysis identifies highly expressed plasma membrane proteins for detection and therapeutic targeting of specific breast cancer subtypes.

Author information

1
1Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL USA.
2
2Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA USA.

Abstract

In recent years, there has been an emphasis on personalizing breast cancer treatment in order to avoid the debilitating side effects caused by broad-spectrum chemotherapeutic drug treatment. Development of personalized medicine requires the identification of proteins that are expressed by individual tumors. Herein, we reveal the identity of plasma membrane proteins that are overexpressed in estrogen receptor α-positive, HER2-positive, and triple negative breast cancer cells. The proteins we identified are involved in maintaining protein structure, intracellular homeostasis, and cellular architecture; enhancing cell proliferation and invasion; and influencing cell migration. These proteins may be useful for breast cancer detection and/or treatment.

KEYWORDS:

Diagnostic markers; Estrogen receptor α-positive breast cancer; HER2-positive breast cancer; Individualized medicine; Plasma membrane proteins; Proteomic analysis; Triple negative breast cancer

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center